Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody J Peer

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Cancer Research|December 16, 2020
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor ModelsShaun D Fontaine, Gary W Ashley, Peter J Houghton, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2020
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumorsKeith T Schmidt, Alwin D R Huitema, Thomas P C Dorlo, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2016
Synthesis of a stable and orally bioavailable englerin analogueDavid M Fash, Cody J Peer, Zhenwu Li, et al.
Neuro-Oncology|February 16, 2024
Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancerVanesa L Silvestri, Andy D Tran, Monika Chung, et al.
Pharmacogenetics and Genomics|February 17, 2017
Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet responseJoshua D Backman, Jeffrey R O'Connell, Keith Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth InhibitionZhenhua Wu, Jean-Simon Suppo, Sarka Tumova, et al.
Frontiers in Pharmacology|August 31, 2016
Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in RatsCody J Peer, Jonathan D Strope, Shaunna Beedie, et al.
Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Cancer Research|December 16, 2020
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor ModelsShaun D Fontaine, Gary W Ashley, Peter J Houghton, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2020
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumorsKeith T Schmidt, Alwin D R Huitema, Thomas P C Dorlo, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2016
Synthesis of a stable and orally bioavailable englerin analogueDavid M Fash, Cody J Peer, Zhenwu Li, et al.
Neuro-Oncology|February 16, 2024
Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancerVanesa L Silvestri, Andy D Tran, Monika Chung, et al.
Pharmacogenetics and Genomics|February 17, 2017
Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet responseJoshua D Backman, Jeffrey R O'Connell, Keith Tanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth InhibitionZhenhua Wu, Jean-Simon Suppo, Sarka Tumova, et al.
Frontiers in Pharmacology|August 31, 2016
Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in RatsCody J Peer, Jonathan D Strope, Shaunna Beedie, et al.
Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Pageof 14